
Abbott Laboratories: updates and filings
Price
$103.82
November 19, 2026Market cap $180B
What Ploutos Investor adds for Abbott Laboratories
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 21, 2026next Jan 15, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
July 2026
April 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Officer or director changeForm8-K
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 21, 2026Other material eventsForm8-K
- Oct 21, 2026Results of operationsForm8-K
- Aug 20, 2026Regulation FD disclosure, other material eventsForm8-K
- Jul 28, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 16, 2026Results of operationsForm8-K
- Jun 18, 2026Employee stock plan reportfor the period to Dec 31, 2025Form11-K
- May 27, 2026Conflict minerals reportFormSD
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 27, 2026Officer or director change, amended articles or bylaws, shareholder voteForm8-K
- Apr 24, 2026Shares registered for employeesFormS-8
- Apr 17, 2026Other material eventsForm8-K
- Apr 16, 2026Results of operationsForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 23, 2026Shares registered for employeesFormS-8
- Mar 23, 2026Other material eventsForm8-K
- Mar 13, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 13, 2026Additional annual meeting materialFormDEFA14A
- Mar 13, 2026Annual meeting proxy statementFormDEF 14A
- Mar 9, 2026Material agreement entered, new material financial obligationForm8-K
- Feb 26, 2026Material agreement enteredForm8-K
- Feb 23, 2026Shelf registration for future offeringsFormS-3ASR
- Feb 20, 2026Amended articles or bylawsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 8-K | Officer or director change | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 21, 2026 | 8-K | Other material events | Document |
| Oct 21, 2026 | 8-K | Results of operations | Document |
| Aug 20, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jul 28, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 16, 2026 | 8-K | Results of operations | Document |
| Jun 18, 2026 | 11-K | Employee stock plan reportfor the period to Dec 31, 2025 | Document |
| May 27, 2026 | SD | Conflict minerals report | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 27, 2026 | 8-K | Officer or director change, amended articles or bylaws, shareholder vote | Document |
| Apr 24, 2026 | S-8 | Shares registered for employees | Document |
| Apr 17, 2026 | 8-K | Other material events | Document |
| Apr 16, 2026 | 8-K | Results of operations | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 23, 2026 | S-8 | Shares registered for employees | Document |
| Mar 23, 2026 | 8-K | Other material events | Document |
| Mar 13, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 13, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 13, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 9, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Feb 26, 2026 | 8-K | Material agreement entered | Document |
| Feb 23, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Feb 20, 2026 | 8-K | Amended articles or bylaws | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Feb 14, 1994: every report, 8-K, meeting and letter. Of its other filings (986 in all), the newest.
The full analysis
What do Abbott Laboratories's filings show?
The filings are where every one of Abbott Laboratories's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.